#Neurocrine Biosciences

2개의 글

17 de junio de 2026

NBIX Neurocrine Biosciences Pronóstico de Acciones 2026: La apuesta de neurociencia que va más allá de Ingrezza

NBIX Neurocrine Biosciences consolida su franquicia de Ingrezza para discinesia tardía mientras lanza Crenessity para hiperplasia suprarrenal congénita: análisis completo del pronóstico 2026 para inversores en acciones de biotech CNS.

NBIX Neurocrine Biosciences Biofarmacéutica CNS

June 17, 2026

NBIX Neurocrine Biosciences Stock Forecast 2026: CNS Biopharma Beyond Ingrezza

NBIX Neurocrine Biosciences 2026 stock forecast: deep-dive into Ingrezza's tardive dyskinesia franchise durability, the Crenessity CAH launch, and whether this CNS biopharma can sustain its valuation as it transitions from one-product dependency to a multi-asset platform.

NBIX Neurocrine Biosciences CNS Biopharma